{"protocolSection": {"identificationModule": {"nctId": "NCT02902809", "orgStudyIdInfo": {"id": "D2210C00029"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma", "officialTitle": "A 52-Week, Open-Label, Multicentre Study to Evaluate the Safety of Tralokinumab in Japanese Adults and Adolescents With Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting \u03b22-Agonist"}, "statusModule": {"statusVerifiedDate": "2019-07", "overallStatus": "TERMINATED", "whyStopped": "The study was terminated due to the discontinuation of the tralokinumab asthma program (as per the results of the Phase III study \\[D2210C00008\\])", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-11-11", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-01-19", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-01-19", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-09-13", "studyFirstSubmitQcDate": "2016-09-13", "studyFirstPostDateStruct": {"date": "2016-09-16", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-01-07", "resultsFirstSubmitQcDate": "2019-07-26", "resultsFirstPostDateStruct": {"date": "2019-09-06", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-07-26", "lastUpdatePostDateStruct": {"date": "2019-09-06", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "A 52-Week, Open-Label, Multicentre Study to Evaluate the Safety of Tralokinumab in Japanese Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid plus Long-Acting \u03b22-Agonist", "detailedDescription": "This is a 52-week, open-label, multi-centre study designed to evaluate the safety of tralokinumab in a fixed 300 mg dose every 2 weeks, administered subcutaneously in adults and adolescents with indequately controlled asthma on medium to high dose inhaled corticosteroid plus long acting \u03b2-2 antagonist. Approximately 26 Japanese subjects will be recruited to receive 22 completed."}, "conditionsModule": {"conditions": ["Inadequately Controlled Asthma"], "keywords": ["open-label study", "tralokinumab", "subcutaneous", "inadequately controlled asthma", "asthma", "medium to high-dose of inhaled corticosteroid", "long-acting \u03b22-agonist"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE", "maskingDescription": "Open label"}}, "enrollmentInfo": {"count": 28, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Open-label study to evaluate safety", "type": "EXPERIMENTAL", "description": "A fixed 300 mg dose every 2 weeks (Q2W) of tralokinumab administered subcutaneously in subjects with inadequately controlled asthma on medium to high-dose of inhaled corticosteroid plus long-acting \u03b22-agonist.", "interventionNames": ["Biological: Tralokinumab open-label"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Tralokinumab open-label", "description": "Subcutaneous injection; fixed dose; 300 mg", "armGroupLabels": ["Open-label study to evaluate safety"], "otherNames": ["Tralokinumab"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)", "description": "An AE was development of an undesirable medical condition or deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to product. An undesirable medical condition can be symptoms, signs or the abnormal results of an investigation. In clinical studies, an AE can include an undesirable medical condition occurring at any time, including run-in or washout periods, even if no study treatment has been administered. A SAE was an AE occurred during any study phase that fulfils one or more of the following criteria: death; immediately life-threatening, in-patient or prolongation of existing hospitalization; persistent or significant disability/incapacity or substantial disruption of ability to conduct normal life functions; congenital abnormality or birth defect; important medical event that may jeopardise participant or may require medical intervention to prevent one of the outcomes listed above.", "timeFrame": "From Screening (Day -14) up to 14 weeks after end of treatment (Week 66)."}, {"measure": "Number of Participants With Clinical Laboratory Abnormalities", "description": "Blood and urine samples for determination of clinical chemistry, haematology and urinalysis parameters were taken at the times. Changes in haematology and clinical chemistry variables between baseline and each subsequent scheduled assessment were evaluated. Baseline is defined as the last available value measured prior to the first dose of study treatment. The change from baseline is defined as the treatment period value minus the baseline period value. Absolute values were compared to the relevant reference range and classified as low (below range), normal (within range or on limits) or high (above range). The AstraZeneca extended reference ranges were used for laboratory variables (where they exist). All values (absolute and change) falling outside the reference ranges were flagged. Urinalysis data were categorised as negative (0), trace or positive (+) at each time point.", "timeFrame": "From Screening (Day -14) up to 14 weeks after end of treatment (Week 66)."}, {"measure": "Number of Participants With Abnormal Physical Examinations", "description": "Physical examination included assessment of general appearance, skin, head and neck (including eyes, ears, nose, mouth and throat), lymph nodes, abdomen, musculoskeletal (including spine and extremities), cardiovascular, respiratory, and neurological systems. Criteria for abnormal physical findings were based on investigator's discretion.", "timeFrame": "From Screening (Day -14) up to 14 weeks after end of treatment (Week 66)."}, {"measure": "Number of Participants With Vital Signs Abnormalities", "description": "Vital signs that were planned to be assessed included parameters such as pulse, systolic blood pressure, diastolic blood pressure, respiration rate and body temperature.", "timeFrame": "From Screening (Day -14) up to 14 weeks after end of treatment (Week 66)."}, {"measure": "Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities", "description": "The ECG assessments were performed using an ECG device prior to blood drawing, spirometry, investigational product administration and bronchodilator administration. ECG data and evaluation was planned to be performed by the site Investigator.", "timeFrame": "At Day -14 and Week 52."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Age 12 - 75 yrs\n2. Documented physician-diagnosed asthma\n3. Documented treatment with inhaled corticosteroid (ICS) at a total daily dose corresponding to \u2265500 \u00b5g fluticasone propionate dry powder formulation equivalents and a long-acting beta-2 agonist (LABA)\n4. Pre-bronchodilator (BD) forced expiratory volume at one second (FEV1) value of \u226540% of their Predicted Normal Value (PNV)\n5. Asthma Control Questionnaire-6 (ACQ-6) score \u22651.5\n\nExclusion Criteria:\n\n1. Pulmonary disease other than asthma\n2. History of anaphylaxis following any biologic therapy\n3. Hepatitis B, C or HIV\n4. Pregnant of breastfeeding\n5. History or cancer\n6. Current tobacco smoking or a history or tobacco smoking for \u226510 pack-years\n7. Previous receipt of tralokinumab", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "maximumAge": "75 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Takeshi Kaneko, MD, PhD", "affiliation": "Yokohama City University Graduate School of Medicine", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Chuo-ku", "zip": "103-0027", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Research Site", "city": "Itabashi-ku", "zip": "173-8610", "country": "Japan", "geoPoint": {"lat": 35.74893, "lon": 139.71497}}, {"facility": "Research Site", "city": "Yokohama-shi", "zip": "236-0004", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}]}, "referencesModule": {"references": [{"pmid": "29536781", "type": "DERIVED", "citation": "Panettieri RA Jr, Wang M, Braddock M, Bowen K, Colice G. Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program. Immunotherapy. 2018 Mar 1;10(6):473-490. doi: 10.2217/imt-2017-0191. Epub 2018 Mar 14."}], "seeAlsoLinks": [{"label": "Statistical Analysis Plan", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4175&filename=D2210C00029_Statistical%20Analysis%20Plan-ed-2_16Feb2018_redacted05Apr2019_Redacted_val.pdf"}, {"label": "Clinical Study Protocol", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4175&filename=d2210c00029-csp-v2_15June2017_redacted05April2019_Redacted_val.pdf"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Of all enrolled participants, 3 were considered screen failures and 28 participants were received study treatment. Following initial screening, there was a run-in period of up to 2 weeks to allow adequate time for eligibility criteria to be evaluated prior to entry to planned 52-week treatment period followed by a 14 week extended follow-up period.", "recruitmentDetails": "Adult participants with asthma inadequately controlled on inhaled corticosteroid plus long-acting beta 2 agonist were recruited at 4 sites in Japan from 01 November 2016 until study termination on 24 January 2018. No adolescent participants were enrolled in the study.", "groups": [{"id": "FG000", "title": "Tralokinumab 300 mg Every 2 Weeks (Q2W)", "description": "Participants were administered with tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks for 52 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "28"}]}, {"type": "Treatment Received", "achievements": [{"groupId": "FG000", "numSubjects": "28"}]}, {"type": "Treatment Completed", "achievements": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "28"}]}], "dropWithdraws": [{"type": "Discontinuation of asthma program", "reasons": [{"groupId": "FG000", "numSubjects": "28"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "The safety analysis set included all participants enrolled and who received at least 1 dose of investigational product irrespective of their protocol adherence and continued participation in the study.", "groups": [{"id": "BG000", "title": "Tralokinumab 300 mg Every 2 Weeks (Q2W)", "description": "Participants were administered with tralokinumab 300 mg subcutaneous injection every 2 weeks for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "28"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "27"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "1"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "47.7", "spread": "10.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "15"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "13"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "28"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "28"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)", "description": "An AE was development of an undesirable medical condition or deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to product. An undesirable medical condition can be symptoms, signs or the abnormal results of an investigation. In clinical studies, an AE can include an undesirable medical condition occurring at any time, including run-in or washout periods, even if no study treatment has been administered. A SAE was an AE occurred during any study phase that fulfils one or more of the following criteria: death; immediately life-threatening, in-patient or prolongation of existing hospitalization; persistent or significant disability/incapacity or substantial disruption of ability to conduct normal life functions; congenital abnormality or birth defect; important medical event that may jeopardise participant or may require medical intervention to prevent one of the outcomes listed above.", "populationDescription": "The safety analysis set included all participants enrolled and who received at least 1 dose of investigational product irrespective of their protocol adherence and continued participation in the study.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From Screening (Day -14) up to 14 weeks after end of treatment (Week 66).", "groups": [{"id": "OG000", "title": "Tralokinumab 300 mg Every 2 Weeks (Q2W)", "description": "Participants were administered with tralokinumab 300 mg subcutaneous injection every 2 weeks for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}]}], "classes": [{"title": "Any AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "21"}]}]}, {"title": "Any AE with outcome of death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Any SAE (including events with outcome of death)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Any AE leading to discontinuation of study drug", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Clinical Laboratory Abnormalities", "description": "Blood and urine samples for determination of clinical chemistry, haematology and urinalysis parameters were taken at the times. Changes in haematology and clinical chemistry variables between baseline and each subsequent scheduled assessment were evaluated. Baseline is defined as the last available value measured prior to the first dose of study treatment. The change from baseline is defined as the treatment period value minus the baseline period value. Absolute values were compared to the relevant reference range and classified as low (below range), normal (within range or on limits) or high (above range). The AstraZeneca extended reference ranges were used for laboratory variables (where they exist). All values (absolute and change) falling outside the reference ranges were flagged. Urinalysis data were categorised as negative (0), trace or positive (+) at each time point.", "populationDescription": "No participants were analysed as the study was terminated due to discontinuation of tralokinumab asthma program. Study was reported in a synopsis format. Individual listings of clinical laboratory parameters were evaluated for safety signal.", "reportingStatus": "POSTED", "timeFrame": "From Screening (Day -14) up to 14 weeks after end of treatment (Week 66).", "groups": [{"id": "OG000", "title": "Tralokinumab 300 mg Every 2 Weeks (Q2W)", "description": "Participants were administered with tralokinumab 300 mg subcutaneous injection every 2 weeks for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Abnormal Physical Examinations", "description": "Physical examination included assessment of general appearance, skin, head and neck (including eyes, ears, nose, mouth and throat), lymph nodes, abdomen, musculoskeletal (including spine and extremities), cardiovascular, respiratory, and neurological systems. Criteria for abnormal physical findings were based on investigator's discretion.", "populationDescription": "The study was terminated due to discontinuation of tralokinumab asthma program. Study was reported in a synopsis format. Individual listings were evaluated for safety signal. Any new finding(s) or aggravated existing finding(s), judged as clinically significant by the Investigator, were reported as an AE.", "reportingStatus": "POSTED", "timeFrame": "From Screening (Day -14) up to 14 weeks after end of treatment (Week 66).", "groups": [{"id": "OG000", "title": "Tralokinumab 300 mg Every 2 Weeks (Q2W)", "description": "Participants were administered with tralokinumab 300 mg subcutaneous injection every 2 weeks for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Vital Signs Abnormalities", "description": "Vital signs that were planned to be assessed included parameters such as pulse, systolic blood pressure, diastolic blood pressure, respiration rate and body temperature.", "populationDescription": "The study was terminated due to discontinuation of tralokinumab asthma program. Study was reported in a synopsis format. Individual listings were evaluated for safety signal. No summary table was developed.", "reportingStatus": "POSTED", "timeFrame": "From Screening (Day -14) up to 14 weeks after end of treatment (Week 66).", "groups": [{"id": "OG000", "title": "Tralokinumab 300 mg Every 2 Weeks (Q2W)", "description": "Participants were administered with tralokinumab 300 mg subcutaneous injection every 2 weeks for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "PRIMARY", "title": "Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities", "description": "The ECG assessments were performed using an ECG device prior to blood drawing, spirometry, investigational product administration and bronchodilator administration. ECG data and evaluation was planned to be performed by the site Investigator.", "populationDescription": "The study was terminated due to discontinuation of tralokinumab asthma program. Study was reported in a synopsis format. Individual listings were evaluated for safety signal. No summary table was developed.", "reportingStatus": "POSTED", "timeFrame": "At Day -14 and Week 52.", "groups": [{"id": "OG000", "title": "Tralokinumab 300 mg Every 2 Weeks (Q2W)", "description": "Participants were administered with tralokinumab 300 mg subcutaneous injection every 2 weeks for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "From Screening (Day -14) to study termination (Approximately 60 weeks).", "description": "The safety analysis set included all participants enrolled and who received at least 1 dose of investigational product irrespective of their protocol adherence and continued participation in the study.", "eventGroups": [{"id": "EG000", "title": "Tralokinumab 300 mg Every 2 Weeks (Q2W)", "description": "Participants were administered with tralokinumab 300 mg subcutaneous injection every 2 weeks for 52 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 28, "seriousNumAffected": 1, "seriousNumAtRisk": 28, "otherNumAffected": 21, "otherNumAtRisk": 28}], "seriousEvents": [{"term": "Chronic tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}], "otherEvents": [{"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 10, "numAtRisk": 28}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 28}]}, {"term": "Oral herpes", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 28}]}, {"term": "Acute sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Cystitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Oral candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Otitis media acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 28}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Tremor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Dry eye", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Hyperaemia", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 28}]}, {"term": "Upper respiratory tract inflammation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 28}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 28}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 28}]}, {"term": "Cheilitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Hepatic function abnormal", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Dermatitis allergic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Dermatitis contact", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Ingrowing nail", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Neck pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Injection site reaction", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 57, "numAffected": 9, "numAtRisk": 28}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Injection site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Injection site swelling", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Thirst", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Aspartate aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 28}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 28}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Study was terminated due to discontinuation of tralokinumab asthma program. Study was reported in a synopsis format. Individual listings of laboratory variables, physical examinations, vitals and ECG were evaluated for safety signal."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Global Clinical Lead", "organization": "AstraZeneca", "email": "ClinicalTrialTransparency@astrazeneca.com", "phone": "+1 301-398-0582"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2017-06-15", "uploadDate": "2019-04-16T10:43", "filename": "Prot_000.pdf", "size": 1038474}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2018-02-16", "uploadDate": "2019-04-16T10:44", "filename": "SAP_001.pdf", "size": 615594}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000911", "term": "Antibodies, Monoclonal"}], "ancestors": [{"id": "D000007155", "term": "Immunologic Factors"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10184", "name": "Immunoglobulins", "relevance": "LOW"}, {"id": "M4225", "name": "Antibodies", "relevance": "LOW"}, {"id": "M4230", "name": "Antibodies, Monoclonal", "asFound": "Prenatal care", "relevance": "HIGH"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}